Briefs & Reports

The Heavy Price of GLP-1 Drugs: How Financialization Drives Pharmaceutical Patent Abuse and Health Inequities for GLP-1 Therapies

This brief examines the financialized business model of Novo Nordisk and Eli Lilly for the leading GLP-1 products Ozempic, Rybelsus, and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide). It shows how these companies are using the patent system as a key tool to maximize revenues, profitability, and shareholder returns. Through the creation of patent thickets,…

Briefs & Reports 17 Apr 2025

Biologics, Biosimilars and Patents: A Beginner’s Guide

Given the recent history of the BPCIA and the ongoing understanding of how the regulatory aspects are working in practice, including the multiple types of biologic products that are covered by the law, it can seem quite a complicated system for those not in the business. It is with this in mind that we created…

Briefs & Reports 13 May 2024

I-MAK & AELP: The Costs of Pharma Cheating

Briefs & Reports 23 Jun 2023

Lowering Prescription Drug Costs by Removing Barriers to Challenging Patents

Briefs & Reports 30 Nov 2021

Imbruvica’s Patent Wall

Briefs & Reports 17 Dec 2020

The Patent System is a Bottleneck for Medicines

Briefs & Reports 17 Dec 2020

Pharmaceutical Patent Myths

Briefs & Reports 17 Dec 2020

Overpatented, Overpriced: Enbrel Special Edition